Cargando…

Simvastatin-romidepsin combination kills bladder cancer cells synergistically

The HMG-CoA reductase inhibitor simvastatin activates AMP-activated protein kinase (AMPK) and thereby induces histone acetylation. We postulated that combining simvastatin with the histone deacetylase (HDAC) inhibitor romidepsin would kill bladder cancer cells by inducing histone acetylation coopera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okubo, Kazuki, Miyai, Kosuke, Kato, Kimi, Asano, Takako, Sato, Akinori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8220249/ https://www.ncbi.nlm.nih.gov/pubmed/34144348 http://dx.doi.org/10.1016/j.tranon.2021.101154

Ejemplares similares

Nelfinavir and Ritonavir Kill Bladder Cancer Cells Synergistically by Inducing Endoplasmic Reticulum Stress
por: Sato, Akinori, et al.
Publicado: (2018)

Ritonavir and ixazomib kill bladder cancer cells by causing ubiquitinated protein accumulation
por: Sato, Akinori, et al.
Publicado: (2017)

Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells
por: Okubo, Kazuki, et al.
Publicado: (2019)

Synergistic Effect of Simvastatin and Romidepsin on Gamma-globin Gene Induction
por: Habibi, Hussain, et al.
Publicado: (2019)

Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells
por: Isono, Makoto, et al.
Publicado: (2021)

Prostate cancer recurrence mimicking invasive urothelial cancer of the bladder
por: Okubo, Kazuki, et al.
Publicado: (2020)

Metformin Augments Panobinostat's Anti-Bladder Cancer Activity by Activating AMP-Activated Protein Kinase()()
por: Okubo, Kazuki, et al.
Publicado: (2019)

Ataxia telangiectasia and Rad3-related inhibition by AZD6738 enhances gemcitabine-induced cytotoxic effects in bladder cancer cells
por: Isono, Makoto, et al.
Publicado: (2022)

Ritonavir Interacts With Belinostat to Cause Endoplasmic Reticulum Stress and Histone Acetylation in Renal Cancer Cells
por: Isono, Makoto, et al.
Publicado: (2016)

Romidepsin-induced neutrophilic urticaria
por: Scott, Brian, et al.
Publicado: (2016)

Romidepsin in the treatment of cutaneous T-cell lymphoma
por: Jain, Salvia, et al.
Publicado: (2011)

Romidepsin for the Treatment of Peripheral T-Cell Lymphoma
por: Barbarotta, Lisa, et al.
Publicado: (2015)

In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial
por: Rosás-Umbert, Miriam, et al.
Publicado: (2020)

Synergistic Anti-Tumor Effect of Simvastatin Combined to Chemotherapy in Osteosarcoma
por: Mangelinck, Adèle, et al.
Publicado: (2021)

Simvastatin Is Effective in Killing the Radioresistant Breast Carcinoma Cells
por: Aschenbrenner, Bertram, et al.
Publicado: (2021)

Use of class I histone deacetylase inhibitor romidepsin in combination regimens
por: Petrich, Adam, et al.
Publicado: (2016)

Deciphering the molecular effects of romidepsin on germ cell tumours: DHRS2 is involved in cell cycle arrest but not apoptosis or induction of romidepsin effectors
por: Nettersheim, Daniel, et al.
Publicado: (2018)

Compensatory combination of romidepsin with gemcitabine and cisplatin to effectively and safely control urothelial carcinoma
por: Pattarawat, Pawat, et al.
Publicado: (2020)

Pharmacokinetics and Immunological Effects of Romidepsin in Rhesus Macaques
por: Kleinman, Adam J., et al.
Publicado: (2020)

Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma
por: Kalac, Matko, et al.
Publicado: (2023)

Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma
por: Foss, Francine, et al.
Publicado: (2014)

Successful response with romidepsin in relapsed peripheral T-cell lymphoma, not otherwise specified with leukemic progression
por: Sato, Shuku, et al.
Publicado: (2020)

Synergistic effects of telmisartan and simvastatin on endothelial progenitor cells
por: Steinmetz, Martin, et al.
Publicado: (2010)

Induction of MAPK- and ROS-dependent autophagy and apoptosis in gastric carcinoma by combination of romidepsin and bortezomib
por: Hui, Kwai Fung, et al.
Publicado: (2015)

The Histone Deacetylase Inhibitor Romidepsin Spares Normal Tissues While Acting as an Effective Radiosensitizer in Bladder Tumors in Vivo
por: Paillas, Salome, et al.
Publicado: (2020)

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
por: Søgaard, Ole S., et al.
Publicado: (2015)

Romidepsin targets multiple survival signaling pathways in malignant T cells
por: Valdez, B C, et al.
Publicado: (2015)

Long-Term Treatment with Romidepsin in Patients with Peripheral T-Cell Lymphoma
por: Irlé, Claudius, et al.
Publicado: (2016)

Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells
por: Sato, Akinori, et al.
Publicado: (2014)

Clinically undetected plasmacytoid urothelial carcinoma of the urinary bladder with non-mass-forming metastases in multiple organs: an autopsy case
por: Asano, Yuya, et al.
Publicado: (2022)

Crosstalk among the proteome, lysine phosphorylation, and acetylation in romidepsin-treated colon cancer cells
por: Wang, Tian-Yun, et al.
Publicado: (2016)

Rapid progression of mucinous tubular and spindle cell carcinoma of the kidney without sarcomatoid changes: A case report
por: Isono, Makoto, et al.
Publicado: (2020)

Immunosuppression-associated primary cutaneous plasmablastic lymphoma secondary to romidepsin
por: Costello, Collin M., et al.
Publicado: (2019)

Synergistic Effects of Simvastatin and Irinotecan against Colon Cancer Cells with or without Irinotecan Resistance
por: Jang, Hyun Joo, et al.
Publicado: (2016)

P1195: A REAL WORLD EXPERIENCE OF COMBINED TREATMENT WITH ROMIDEPSIN AND AZACITIDINE IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA.
por: Kalac, M., et al.
Publicado: (2022)

Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T‐cell lymphoma
por: Foss, Francine, et al.
Publicado: (2016)

Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T‐cell lymphoma
por: Pro, Barbara, et al.
Publicado: (2016)

Romidepsin Induces G2/M Phase Arrest and Apoptosis in Cholangiocarcinoma Cells
por: Li, Pihong, et al.
Publicado: (2020)

Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin
por: Sager, Philip T, et al.
Publicado: (2015)

Romidepsin Controls Chronic Lymphocytic Leukemia in a Patient with Mycosis Fungoides
por: Lemchak, David. M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nstjle4pjkjhtrevk0q11t9nbc